INS and type 1 diabetes mellitus: Considering the APC function of insulin-reactive B cells, in addition to the proof-of-concept therapeutic outcomes of broadly targeting the B cell compartment in both mouse and human T1D, we designed a novel antigen-specific immunotherapy (ASI), AKS-107, that specifically targets insulin-reactive B cells for deletion.